Table Info

Table 1.

Differences in baseline characteristics between patients with cardiotoxicity and those who don’t have cardiotoxicity

Variables	Patients with cardiotoxicity N = 34	Patients without cardiotoxicity N = 146	P
Age (years)	55	54.4	0.442
Gender
Male	11.8%	14.4%	0.468
Female	88.2%	85.6%	0.468
Systemic arterial hypertension	29.4%	27.4%	0.483
Diabetes	14.7%	19%	0.490
Dyslipidemia	8.8%	9.6%	0.595
Smoking	5.9%	15.1%	0.124
Systolic blood pressure (mmHg)	127.7	123.1	0.121
Diastolic blood pressure (mmHg)	74.7	72.8	0.141
BMI (kg/m²)	27.8	26	0.078
Cancer type
Lymphoma	6.1%	6.2%	0.547
Breast cancer	74.5%	72.6%
Leukemia	2.7%	3.4%
Others	16.6%	17.8%
Treatment
Anthracyclines	75%	55.9%	0.034
HER2	68.8%	57.9%	0.176
Fluoropyrimidines	9.4%	9.0%	0.582
Multi-targeted kinase inhibitors BCR-ABL	0%	4.1%	0.297
Androgen deprivation	0%	5.5%	0.196
Endocrine therapy for breast cancer	6%	35%	0.345
Epidermal growth factor receptor inhibitors	0%	0.7%	0.824
Radiation therapy	15.2%	23.3%	0.219
Others	78.1%	70.3%	0.256
Combination chemotherapy and radiation therapy	46.9%	48.6%	0.707

BMI: body mass index

Supplementary materials

The supplementary material for this article is available at: https://www.explorationpub.com/uploads/Article/file/101254_sup_1.pdf.

Declarations

Acknowledgments

We would like to express our gratitude to the entire echocardiography service at the Cabinet Department of the National Medical Center 21st century as they were instrumental in-patient recruitment during this time. We also want to thank Dr. Daniel Calderón Rodríguez from the Nuclear Medicine service at the Cardiology Hospital, National Medical Center 21st century, and Dr. Rubén Fernández Galera from Vall d’Hebron Hospital for their contribution with nuclear medicine and cardiac magnetic resonance images.

Author contributions

DCP: Investigation, Writing—original draft. DRZ: Formal analysis, Methodology. GRG: Validation, Investigation. ICG: Investigation, Validation. CMH: Conceptualization, Project administration.

Conflicts of interest

The authors declare that they have no conflicts of interest.

Ethical approval

The study was approved by the local health research committee 3604, Cardiology Hospital National Medical Center 21st century, Registration number R-2023-3604-056.

Consent to participate

Informed consent to participate in the study was obtained from all participants.

Consent to publication

Not applicable.

Availability of data and materials

We have the database of this study electronically, if you need this or revision of any data, we will gladly send it to you, contact dnicrck@hotmali.com.

Funding

Not applicable.

Copyright

Publisher’s note

Open Exploration maintains a neutral stance on jurisdictional claims in published institutional affiliations and maps. All opinions expressed in this article are the personal views of the author(s) and do not represent the stance of the editorial team or the publisher.

References

Albini A, Pennesi G, Donatelli F, Cammarota R, De Flora S, Noonan DM. Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention. J Natl Cancer Inst. 2010;102:14–25. [DOI] [PubMed] [PMC]

Yeh ET, Bickford CL. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol. 2009;53:2231–47. [DOI] [PubMed]

Florescu M, Cinteza M, Vinereanu D. Chemotherapy-induced Cardiotoxicity. Maedica (Bucur). 2013;8:59–67. [PubMed] [PMC]

Zamorano JL, Gottfridsson C, Asteggiano R, Atar D, Badimon L, Bax JJ, et al. The cancer patient and cardiology. Eur J Heart Fail. 2020;22:2290–309. [DOI] [PubMed] [PMC]

Dhir AA, Sawant SP. Cardiac morbidity & mortality in patients with breast cancer: A review. Indian J Med Res. 2021;154:199–209. [DOI] [PubMed] [PMC]

Stone JR, Kanneganti R, Abbasi M, Akhtari M. Monitoring for Chemotherapy-Related Cardiotoxicity in the Form of Left Ventricular Systolic Dysfunction: A Review of Current Recommendations. JCO Oncol Pract. 2021;17:228–36. [DOI] [PubMed]

Shaikh F, Dupuis LL, Alexander S, Gupta A, Mertens L, Nathan PC. Cardioprotection and Second Malignant Neoplasms Associated With Dexrazoxane in Children Receiving Anthracycline Chemotherapy: A Systematic Review and Meta-Analysis. J Natl Cancer Inst. 2015;108:djv357. [DOI] [PubMed]

Herbrecht R, Cernohous P, Engert A, Le Gouill S, Macdonald D, Machida C, et al. Comparison of pixantrone-based regimen (CPOP-R) with doxorubicin-based therapy (CHOP-R) for treatment of diffuse large B-cell lymphoma. Ann Oncol. 2013;24:2618–23. [DOI] [PubMed]

Cardinale D, Iacopo F, Cipolla CM. Cardiotoxicity of Anthracyclines. Front Cardiovasc Med. 2020;7:26. [DOI] [PubMed] [PMC]

10.

Tang CPS, McMullen J, Tam C. Cardiac side effects of bruton tyrosine kinase (BTK) inhibitors. Leuk Lymphoma. 2018;59:1554–64. [DOI] [PubMed]

11.

Ewer SM, Ewer MS. Cardiotoxicity profile of trastuzumab. Drug Saf. 2008;31:459–67. [DOI] [PubMed]

12.

Villarraga HR, Herrmann J, Nkomo VT. Cardio-oncology: role of echocardiography. Prog Cardiovasc Dis. 2014;57:10–8. [DOI] [PubMed]

13.

Baldassarre LA, Ganatra S, Lopez-Mattei J, Yang EH, Zaha VG, Wong TC, et al.; ACC Cardio-Oncology and the ACC Imaging Councils. Advances in Multimodality Imaging in Cardio-Oncology: JACC State-of-the-Art Review. J Am Coll Cardiol. 2022;80:1560–78. [DOI] [PubMed]

14.

Bird BR, Swain SM. Cardiac toxicity in breast cancer survivors: review of potential cardiac problems. Clin Cancer Res. 2008;14:14–24. [DOI] [PubMed]

15.

Lyon AR, López-Fernández T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, et al.; ESC Scientific Document Group. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J. 2022;43:4229–361. [DOI] [PubMed]

16.

Dobson R, Ghosh AK, Ky B, Marwick T, Stout M, Harkness A, et al.; British Society of Echocardiography (BSE) and theBritish Society of Cardio-Oncology (BCOS). BSE and BCOS Guideline for Transthoracic Echocardiographic Assessment of Adult Cancer Patients Receiving Anthracyclines and/or Trastuzumab. JACC CardioOncol. 2021;3:1–16. [DOI] [PubMed] [PMC]

17.

Suwatanaviroj T, He W, Pituskin E, Paterson I, Choy J, Becher H. What is the minimum change in left ventricular ejection fraction, which can be measured with contrast echocardiography? Echo Res Pract. 2018;5:71–7. [DOI] [PubMed] [PMC]

18.

Santoro C, Arpino G, Esposito R, Lembo M, Paciolla I, Cardalesi C, et al. 2D and 3D strain for detection of subclinical anthracycline cardiotoxicity in breast cancer patients: a balance with feasibility. Eur Heart J Cardiovasc Imaging. 2017;18:930–6. [DOI] [PubMed]

19.

Yang H, Wright L, Negishi T, Negishi K, Liu J, Marwick TH. Research to Practice: Assessment of Left Ventricular Global Longitudinal Strain for Surveillance of Cancer Chemotherapeutic-Related Cardiac Dysfunction. JACC Cardiovasc Imaging. 2018;11:1196–201. [DOI] [PubMed] [PMC]

20.

Mirea O, Pagourelias ED, Duchenne J, Bogaert J, Thomas JD, Badano LP, et al.; EACVI-ASE-Industry Standardization Task Force. Variability and Reproducibility of Segmental Longitudinal Strain Measurement: A Report From the EACVI-ASE Strain Standardization Task Force. JACC Cardiovasc Imaging. 2018;11:15–24. [DOI] [PubMed]

21.

Bhagat AA, Kalogeropoulos AP, Baer L, Lacey M, Kort S, Skopicki HA, et al. Biomarkers and Strain Echocardiography for the Detection of Subclinical Cardiotoxicity in Breast Cancer Patients Receiving Anthracyclines. J Pers Med. 2023;13:1710. [DOI] [PubMed] [PMC]

22.

Kosmala W, Negishi T, Thavendiranathan P, Penicka M, De Blois J, Murbræch K, et al. Incremental Value of Myocardial Work over Global Longitudinal Strain in the Surveillance for Cancer-Treatment-Related Cardiac Dysfunction: A Case-Control Study. J Clin Med. 2022;11:912. [DOI] [PubMed] [PMC]

23.

Asch FM, Miyoshi T, Addetia K, Citro R, Daimon M, Desale S, et al.; WASE Investigators. Similarities and Differences in Left Ventricular Size and Function among Races and Nationalities: Results of the World Alliance Societies of Echocardiography Normal Values Study. J Am Soc Echocardiogr. 2019;32:1396–406.e2. [DOI] [PubMed]

24.

Shiino K, Yamada A, Ischenko M, Khandheria BK, Hudaverdi M, Speranza V, et al. Intervendor consistency and reproducibility of left ventricular 2D global and regional strain with two different high-end ultrasound systems. Eur Heart J Cardiovasc Imaging. 2017;18:707–16. [DOI] [PubMed]

25.

Li X, Zhang P, Li M, Zhang M. Myocardial work: The analytical methodology and clinical utilities. Hellenic J Cardiol. 2022;68:46–59. [DOI] [PubMed]

26.

Russell K, Eriksen M, Aaberge L, Wilhelmsen N, Skulstad H, Remme EW, et al. A novel clinical method for quantification of regional left ventricular pressure-strain loop area: a non-invasive index of myocardial work. Eur Heart J. 2012;33:724–33. [DOI] [PubMed] [PMC]

27.

Hubert A, Le Rolle V, Leclercq C, Galli E, Samset E, Casset C, et al. Estimation of myocardial work from pressure-strain loops analysis: an experimental evaluation. Eur Heart J Cardiovasc Imaging. 2018;19:1372–9. [DOI] [PubMed]

28.

Chan J, Edwards NFA, Khandheria BK, Shiino K, Sabapathy S, Anderson B, et al. A new approach to assess myocardial work by non-invasive left ventricular pressure-strain relations in hypertension and dilated cardiomyopathy. Eur Heart J Cardiovasc Imaging. 2019;20:31–9. [DOI] [PubMed]

29.

Manganaro R, Marchetta S, Dulgheru R, Ilardi F, Sugimoto T, Robinet S, et al. Echocardiographic reference ranges for normal non-invasive myocardial work indices: results from the EACVI NORRE study. Eur Heart J Cardiovasc Imaging. 2019;20:582–90. [DOI] [PubMed]